These molecular mechanisms provide a comprehensive framework for understanding how RUNX3 down-regulation contributes to VOC pathophysiology and supports its potential as a biomarker for VOC in SCD patients. This evidence concerns the gene RUNX3 and Schnyder corneal dystrophy.